NiSource Free cash flow decreased by 171.4% to -$362.90M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 839.1%, from $49.10M to -$362.90M. Over 4 years (FY 2021 to FY 2025), Free cash flow shows an upward trend with a -9.3% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
An increase suggests improved operational efficiency or reduced capital intensity, providing more flexibility for capital allocation. A decrease may indicate higher investment in R&D or infrastructure, or potential challenges in converting earnings into cash.
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and m...
Large-cap medical device and pharmaceutical peers typically maintain strong, positive free cash flow, though levels vary based on the intensity of R&D spending and the lifecycle stage of major product lines.
free_cash_flow| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | -$176.40M | -$258.40M | -$266.60M | $129.70M | -$139.50M | -$477.00M | -$306.90M | $126.30M | -$97.20M | -$378.80M | -$361.00M | -$133.30M | -$184.30M | -$294.70M | -$220.20M | $49.10M | -$162.80M | -$172.60M | -$133.70M | -$362.90M |
| QoQ Change | — | -46.5% | -3.2% | +148.6% | -207.6% | -241.9% | +35.7% | +141.2% | -177.0% | -289.7% | +4.7% | +63.1% | -38.3% | -59.9% | +25.3% | +122.3% | -431.6% | -6.0% | +22.5% | -171.4% |
| YoY Change | — | — | — | — | +20.9% | -84.6% | -15.1% | -2.6% | +30.3% | +20.6% | -17.6% | -205.5% | -89.6% | +22.2% | +39.0% | +136.8% | +11.7% | +41.4% | +39.3% | -839.1% |